Activation of blood coagulation in cancer: Trousseau's syndrome revisited.
D000906:Antibodies / Q000276:immunology; D001241:Aspirin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000150:complications; D001779:Blood Coagulation Factors / Q000096:biosynthesis; D001792:Blood Platelets / Q000276:immunology; D002448:Cell Adhesion; D002450:Cell Communication; D016861:Cyclooxygenase Inhibitors; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D011464:Epoprostenol / Q000627:therapeutic use; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000096:biosynthesis; D005344:Fibrinopeptide A / Q000032:analysis; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D009000:Monocytes / Q000502:physiology; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D013577:Syndrome; D013921:Thrombocytopenia / Q000150:complications; D013922:Thrombocytosis / Q000150:complications; D013923:Thromboembolism / Q000150:complications*; D013925:Thromboplastin / Q000502:physiology
D000906:Antibodies; D001779:Blood Coagulation Factors; D016861:Cyclooxygenase Inhibitors; D005338:Fibrin Fibrinogen Degradation Products; D005344:Fibrinopeptide A; D005340:Fibrinogen; D013925:Thromboplastin; D011464:Epoprostenol; D001241:Aspirin; D007213:Indomethacin